Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

• Published in: Advances in therapy Vol. 35; no. 11; pp. 1920 - 1934
• Main Authors: Salavert, Miguel, Cobo, Javier, Pascual, Álvaro, Aragón, Belén, Maratia, Stefano, Jiang, Yiling, Aceituno, Susana, Grau, Santiago
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.11.2018
• Subjects: Cardiology; Endocrinology; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Original Research; Pharmacology/Toxicology; Rheumatology; Cost-effectiveness; infection; Bezlotoxumab; Clostridium difficile infection

Introduction Clostridium difficile infection (CDI) is the major cause of infectious nosocomial diarrhoea and is associated with considerable morbidity, mortality and economic impact. Bezlotoxumab administered in combination with standard of care (SoC) antibiotic therapy prevents recurrent CDI. This...